Studies link GLP-1 drugs to lower rates of several obesity-related cancers, but researchers say the evidence does not yet prove cancer prevention
Could a class of drugs originally developed to treat diabetes and later transformed into a blockbuster treatment for weight loss offer another, very different benefit?
Researchers are now examining that possibility as growing evidence suggests that GLP-1 drugs, including semaglutide, may be associated with a lower risk of developing or progressing certain cancers.
Growing body of evidence
The issue has attracted significant attention in cancer research. At the annual meeting of the American Society of Clinical Oncology (ASCO), researchers presented new data linking GLP-1 treatments to lower rates of some cancers, a reduced likelihood of metastasis and improved survival among some patients.
A 2024 study involving more than 1.6 million people with type 2 diabetes found lower rates of 10 of 13 obesity-related cancers among people taking GLP-1 drugs compared with those taking insulin.
Study involving 87,000 adults
A year later, another study involving about 87,000 adults found that people who started GLP-1 treatment had an approximately 17% lower overall incidence of cancer.
The largest reductions involved endometrial cancer, ovarian cancer and meningioma, a type of brain tumour.
Scientists call for more evidence
The findings have generated considerable interest, but researchers stress that they do not yet establish that GLP-1 drugs themselves prevent cancer.
Ziyad Al-Aly, a physician and clinical epidemiologist at Washington University in St. Louis, has warned that public headlines have moved faster than the science.
The fact that studies find a lower cancer risk among GLP-1 users does not automatically mean that the drugs caused that reduction.
The challenge of observational studies
Researchers face a major challenge because most studies conducted so far have been observational. They compare people taking GLP-1 drugs with people who do not take them, but the two groups may differ in important ways from the outset.
People who have access to these medications, for example, may receive more regular medical care, have better access to healthcare or follow different lifestyles.
Al-Aly also points out that cancer generally takes years to develop. When a study records a striking reduction in cancer risk soon after people begin treatment, researchers cannot easily determine whether the drugs produced a genuine anti-cancer effect or whether the result reflects characteristics shared by the people who started taking them.
A revolution in obesity treatment
These questions explain why researchers continue to invest in larger and longer-term studies.
“There is no doubt that GLP-1 drugs, such as semaglutide and liraglutide, as well as newer GLP-1/GIP drugs such as tirzepatide, have revolutionised the treatment of obesity,” says Theodora Psaltopoulou, a physician and professor of Therapeutic Epidemiology and Preventive Medicine at the National and Kapodistrian University of Athens.
“When it comes to cancer, however, research is still ongoing,” she stresses.
Four key questions remain
Psaltopoulou highlights four major questions that researchers still need to answer.
1. Can GLP-1 drugs cause cancer?
Current evidence offers some reassurance.
Large meta-analyses have not found an overall increase in cancer risk among people taking GLP-1 drugs.
2. Could GLP-1 drugs protect against some cancers?
Researchers have found indications that the drugs could offer protection against certain cancers, although that effect may not apply equally across the population.
Randomised clinical trials and their meta-analyses suggest that a protective effect may exist for some cancers, but researchers do not yet have enough evidence to describe GLP-1 drugs as proven cancer-prevention treatments.
3. Could the drugs improve outcomes for people who already have cancer?
This represents another major area of research.
Scientists are investigating whether GLP-1 drugs could improve outcomes during cancer treatment, including alongside immunotherapy, or after treatment ends.
Several biological mechanisms could potentially explain such an effect. These include reductions in obesity, hyperinsulinemia and chronic inflammation, as well as possible direct effects on cancer and immune cells.
Clinical trials are already examining these possibilities. Researchers also need to determine whether the effects depend on the dose or duration of treatment.
4. How reliable are the studies?
The type of study matters greatly when researchers assess the evidence.
Scientists must distinguish between observational studies, randomised clinical trials and real-world data from electronic health records, such as those available in the United States and Scandinavian countries.
These different approaches can produce different levels of evidence and help researchers determine whether an apparent association represents a genuine causal effect.
More research needed
For now, researchers say the evidence remains promising but incomplete.
GLP-1 drugs have clearly transformed the treatment of obesity, but their potential role in cancer prevention or treatment requires further investigation.
“More analyses and publications” are needed before scientists can draw firm conclusions, Psaltopoulou says.
Until then, GLP-1 drugs should remain prescribed according to their approved indications and current clinical guidelines, with appropriate medical supervision.